An open-label, single-center, crossover study to evaluate the impact of administration timing of TS-172 on the pharmacodynamics in healthy adult male subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Urinaly excretion of phosphorus
Time frame: Up to 3 days postdose during each period
Urinaly excretion of sodium
Time frame: Up to 3 days postdose during each period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.